ENSC insider filings

Ensysce Biosciences, Inc. — 32 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-18. Screen ENSC transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for ENSC between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Ensysce Biosciences, Inc.

FiledFormInsiderReported transactionsSource
2026-08-184GOWER BOB G — DirectorPurchase (P): 508,614 @ $0.48 · Purchase (P): 400,000 @ $0.49 · Conversion (C): 254,307 (derivative)EDGAR
2023-03-064GOWER BOB G — DirectorPurchase (P): 90,287 @ $0.49EDGAR
2023-03-024GOWER BOB G — DirectorPurchase (P): 109,300 @ $0.49 · Purchase (P): 270,000 @ $0.48EDGAR
2023-02-014GOWER BOB G — DirectorPurchase (P): 357,143 @ $1.40 · Grant/award (A): 714,286 (derivative)EDGAR
2022-06-274Rauch Lee M. — DirectorGrant/award (A): 15,000 (derivative)EDGAR
2022-06-274Rosebraugh Curtis — DirectorGrant/award (A): 20,000 (derivative)EDGAR
2022-06-274Benton Andrew — DirectorGrant/award (A): 15,000 (derivative)EDGAR
2022-06-274Levin Adam — DirectorGrant/award (A): 15,000 (derivative)EDGAR
2022-06-274Chang William H — Director, 10% ownerGrant/award (A): 15,000 (derivative)EDGAR
2022-06-274Martin Steven Robert — DirectorGrant/award (A): 15,000 (derivative)EDGAR
2022-06-274GOWER BOB G — Director, 10% ownerGrant/award (A): 15,000 (derivative)EDGAR
2022-05-274Kirkpatrick Lynn — Chief Executive Officer, DirectorPurchase (P): 70,000 @ $0.49 · Purchase (P): 27,000 @ $0.53 · Grant/award (A): 200,000 (derivative)EDGAR
2022-02-244Birkett Kevin Geoffrey — Chief Commercial OfficerGrant/award (A): 50,000 (derivative)EDGAR
2022-02-244Humphrey David Carl — Chief Financial OfficerGrant/award (A): 80,000 (derivative)EDGAR
2022-02-244Kirkpatrick Lynn — Chief Executive Officer, DirectorGrant/award (A): 200,000 (derivative)EDGAR
2022-02-044Benton Andrew — DirectorGrant/award (A): 20,000 (derivative)EDGAR
2022-02-044Levin Adam — DirectorGrant/award (A): 20,000 (derivative)EDGAR
2022-02-044Rosebraugh Curtis — DirectorGrant/award (A): 20,000 (derivative)EDGAR
2022-02-044Pestano Linda — Chief Development OfficerGrant/award (A): 200,000 (derivative)EDGAR
2022-02-044Humphrey David Carl — Chief Financial OfficerGrant/award (A): 275,000 (derivative)EDGAR
2022-02-044Chang William H — Director, 10% ownerGrant/award (A): 20,000 (derivative)EDGAR
2022-02-044Martin Steven Robert — DirectorGrant/award (A): 20,000 (derivative)EDGAR
2022-02-044GOWER BOB G — Director, 10% ownerGrant/award (A): 20,000 (derivative)EDGAR
2021-07-024Benton Andrew — DirectorGrant/award (A): 65,850 (derivative)EDGAR
2021-07-024Humphrey David Carl — Chief Financial OfficerGrant/award (A): 50,000 @ $0EDGAR
2021-07-024Wright Richard Chester — Chief Business OfficerGrant/award (A): 49,975 (derivative) · Grant/award (A): 65,850 (derivative) · Grant/award (A): 263,400 (derivative) · Grant/award (A): 19,755 (derivative) · Grant/award (A): 987,750 (derivative)EDGAR
2021-07-024Birkett Kevin Geoffrey — Chief Commercial OfficerGrant/award (A): 19,755 (derivative) · Grant/award (A): 329,250 (derivative)EDGAR
2021-07-024Chang William H — Director, 10% ownerGrant/award (A): 353,451 · Grant/award (A): 2,242,189EDGAR
2021-07-024Kirkpatrick Lynn — Chief Executive Officer, DirectorGrant/award (A): 284,851 · Grant/award (A): 99,950 (derivative) · Grant/award (A): 9,994 (derivative) · Grant/award (A): 263,400 (derivative) · Grant/award (A): 460,950 (derivative) · Grant/award (A): 817,560 (derivative) · +2 moreEDGAR
2021-07-024Martin Steven Robert — DirectorGrant/award (A): 65,850 (derivative)EDGAR
2021-07-024Schmidt William K — Chief Medical OfficerGrant/award (A): 69,142 (derivative)EDGAR
2021-07-024GOWER BOB G — Director, 10% ownerGrant/award (A): 7,919,026 · Grant/award (A): 6,585 (derivative)EDGAR

Recent 8-K events — Ensysce Biosciences, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-048-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-168-K/A9.01 — Financial Statements and ExhibitsEDGAR
2026-09-298-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-258-K8.01 — Other EventsEDGAR
2026-08-248-K8.01 — Other EventsEDGAR
2026-08-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-068-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.02 — Unregistered Sales of Equity Securities
3.03 — Material Modification to Rights of Security Holders
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-068-K/A9.01 — Financial Statements and ExhibitsEDGAR
2026-07-158-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ENSC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs